Jahn Claus E, Strotmann Heike
Augenpraxisklinik Dr. Jahn, Kempten, Germany.
Ophthalmologica. 2005 Nov-Dec;219(6):362-5. doi: 10.1159/000088379.
To report the safety of a newly developed intraocular lens (PC/IOL) with reversibly adjustable refractive power (*Acri.Tec AR-1 PC/IOL) after implantation into adult human eyes. The surgical setup and specially designed instruments required for implantation will be evaluated. The examined parameters included: stability of the IOL during implantation, positioning of the IOL, rotation of the IOL, integrity of the posterior lens capsule, central visual acuity, morphology of the eye, clinical signs of inflammation, intraocular pressure, refraction.
The study was carried out on 35 human eyes after using the Acri.Tec AR-1 PC/IOL after lens removal through phacoemulsification; as control, the implantation of conventional PC/IOL into the second eye of 29 patients was used. The mean follow-up was 9 + 6 months. An initial adjustment surgery of the *Acri.Tec AR-1 PC/IOL was carried out 2 weeks after implantation in 2 patients; the follow-up of these eyes was 3 and 6 months.
Implantation was possible without any problem. Eyes healed normally. No difference between eyes containing the *Acri.Tec AR-1 PC/IOL and eyes containing conventional PC/IOLs could be detected with respect to visual acuity, stabilization of refractive error, signs of inflammatory reaction, slitlamp microscopic aspect of the eye and intraocular pressure. As intended, initial adjustment surgery successfully changed the mydriatic refraction from +1.0 resp. +0.75 dpt to 0 resp. -0.5 dpt. 26 bilaterally pseudophakic patients including 2 patients having had adjustment surgery had more than 3 months follow-up. Mean visual acuity in the AR-1 PC/IOL group at 3 months (0.76 +/-0.24) did not differ from mean visual acuity in the pseudophakic control group (0.74 +/-0.23). Adjusted eyes had a visual acuity of 1.0. No adverse effects occurred.
Initial data suggest that the *Acri.Tec AR-1 PC/IOL can be safely implanted into the capsular bag of adult human eyes and can beadjusted after implantation, thereby achieving the desired change of refraction. Further exploration of the potential usefulness of this type of reversibly adjustable PC/IOL as a tool for refractive optimization is warranted.
报告一种新开发的具有可逆可调屈光力的人工晶状体(PC/IOL,Acri.Tec AR-1 PC/IOL)植入成年人类眼睛后的安全性。将评估植入所需的手术设置和专门设计的器械。所检查的参数包括:人工晶状体植入过程中的稳定性、人工晶状体的定位、人工晶状体的旋转、晶状体后囊膜的完整性、中心视力、眼部形态、炎症的临床体征、眼压、屈光。
对35只人眼进行研究,在通过超声乳化摘除晶状体后使用Acri.Tec AR-1 PC/IOL;作为对照,将传统PC/IOL植入29例患者的另一只眼中。平均随访时间为9±6个月。2例患者在植入后2周对Acri.Tec AR-1 PC/IOL进行了初次调整手术;这些眼睛的随访时间为3个月和6个月。
植入过程顺利,无任何问题。眼睛正常愈合。在视力、屈光不正稳定性、炎症反应体征、眼部裂隙灯显微镜检查情况和眼压方面,含Acri.Tec AR-1 PC/IOL的眼睛与含传统PC/IOL 的眼睛之间未检测到差异。如预期的那样,初次调整手术成功地将散瞳验光从+1.0或+0.75屈光度分别改变为0或-0.5屈光度。26例双侧人工晶状体植入患者(包括2例接受调整手术的患者)随访时间超过3个月。AR-1 PC/IOL组3个月时的平均视力(0.76±0.24)与人工晶状体植入对照组的平均视力(0.74±0.23)无差异。调整后的眼睛视力为1.0。未出现不良反应。
初步数据表明,Acri.Tec AR-1 PC/IOL可安全植入成年人类眼睛的囊袋中,并且植入后可进行调整,从而实现所需的屈光改变。有必要进一步探索这种可逆可调PC/IOL作为屈光优化工具的潜在用途。